Browse
Publications
Preprints
About
About UCL Open: Env.
Aims and Scope
Editorial Board
Indexing
APCs
How to cite
Publishing policies
Editorial policy
Peer review policy
Equality, Diversity & Inclusion
About UCL Press
Contact us
For authors
Information for authors
How it works
Benefits of publishing with us
Submit
How to submit
Preparing your manuscript
Article types
Open Data
ORCID
APCs
Contributor agreement
For reviewers
Information for reviewers
Review process
How to peer review
Peer review policy
My ScienceOpen
Sign in
Register
Dashboard
Search
Browse
Publications
Preprints
About
About UCL Open: Env.
Aims and Scope
Editorial Board
Indexing
APCs
How to cite
Publishing policies
Editorial policy
Peer review policy
Equality, Diversity & Inclusion
About UCL Press
Contact us
For authors
Information for authors
How it works
Benefits of publishing with us
Submit
How to submit
Preparing your manuscript
Article types
Open Data
ORCID
APCs
Contributor agreement
For reviewers
Information for reviewers
Review process
How to peer review
Peer review policy
My ScienceOpen
Sign in
Register
Dashboard
Search
1
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,561
similar
All similar
Record
: found
Abstract
: not found
Book
: not found
Allergan Receives FDA Complete Response Letter for Migraine Drug Semprana
Author(s):
Publication date:
2014
Read this book at
Bookmark
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Drug Repurposing Research Collection
Data availability:
Comments
Comment on this book
Sign in to comment
Similar content
2,561
FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market
Authors:
Allergan Completes Acquisition of Oculex Pharmaceuticals, Inc
Authors:
Allergan Pharmaceuticals. Dalbavancin
Authors:
See all similar
Cited by
1
STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD
®
) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
Authors:
Timothy Smith
,
Paul Winner
,
Sheena Aurora
…
See all cited by